issue contents
September 2026 issue
Early view articles
CCP4
Free 

The Guest Editors introduce the special issue based on talks at the CCP4 Study Weekend 2024. The virtual issue is available at https://journals.iucr.org/special_issues/2026/CCP42024/.
Open
access
accessFlawed protein–ligand X-ray structures can misdirect drug discovery based on PDB-deposited models. This review uses publicly available PDB examples to highlight potential pitfalls, from absent ligands to incorrect chemistry, and presents a practical validation approach to improve model reliability.
ISDSB2025
Open
access
accessHere, we describe the determination of the highest resolution structure in the PDB at 0.43 Å resolution. Electron-density maps reveal extensive deformation electron density that is completely accounted for by performing transferable aspherical atom refinements using the DiSCaMB library in BUSTER.
cryoem in the fast lane of structural biology
Open
access
accessWe describe a new method to prepare grids for cryoEM on the sub-millisecond timescale.
research papers
Open
access
accessThe oligomerization of B. melitensis bacterioferritin (BmBfr) was studied using X-ray crystallography, size-exclusion chromatography and thermal shift analysis. These techniques allowed the characterization of both apo and holo BmBfr, highlighting the impact of heme and pH on the oligomerization mechanism.
PDB reference: apo bacterioferritin from Brucella melitentsis, 9gzu
Open
access
accessWe report a room-temperature serial synchrotron X-ray crystallographic structural analysis of Nitratidesulfovibrio vulgaris formate dehydrogenase AB, an enzyme that reduces CO2 to formate.
We determined crystal structures of TCR 4414A bound to HLA-A2-presented p53Y220D and of the corresponding unbound wild-type and mutant p53–HLA-A2 ligands, revealing that the Y220D driver mutation reshapes the peptide and renders a normally cryptic self-epitope visible to T cells. These structures explain how TCR 4414A achieves high specificity for mutant p53 by minimizing interactions with conserved peptide regions and instead focusing on the central Y220D mutation, providing a structural basis for mutation-specific TCR immunotherapy.

journal menu







